Clinical trials: Hepatitis A
Hepatitis B, Chronic
Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).
AB-10-8003 is a randomized, multi-center phase II study to evaluate the efficacy and safety of AHB-137 in subjects with HBeAg-negative CHB under stable NA treatment.
- Trial name
- NCT06550128
- Testing
- AHB-137 (24 weeks), AHB-137 (16 weeks)
- Where
- 6 sites in China
- Volunteers
- 86 people
- Sponsor
- Ausper Biopharma Co., Ltd.
Pneumococcal Immunisation, Diphtheria Immunisation
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
Primary objectives: To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection).
- Conditions
- Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation
- Trial name
- NCT04398706
- Testing
- Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3
- Where
- 57 sites in United States, Canada and 2 more
- Volunteers
- 852 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic
A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected Patients
- Conditions
- Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis, Treatment naïve
- Trial name
- NCT04155515
- Testing
- TG-2349, DAG181, Ribavirin
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
HIV/HCV Co-infection, HIV Infections
Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r
The aim of this study is to assess the efficacy of lopinavir/r in monotherapy and peg-interferon plus ribavirin for the control of both HIV and HCV infection respectively after 12 months of active treatment for HCV.
- Trial name
- PEKARI (NCT00866021)
- Testing
- Lopinavir/ritonavir, Lopinavir/ritonavir with two nucleoside analogs
- Where
- 10 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Fundacion SEIMC-GESIDA
Hepatitis C
Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants
The purpose of this study is to determine whether multiple doses of darunavir/ritonavir or lopinavir/ritonavir affect the pharmacokinetics of daclatasvir in healthy participants.
- Trial name
- NCT02159352
- Testing
- Daclatasvir, Darunavir, Ritonavir
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive chronic hepatitis B (CHB) and low hepatitis B surface antigen (HBsAg) levels.
- Trial name
- NCT04684914
- Testing
- HepTcell
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 87 people
- Sponsor
- Altimmune, Inc.
Obesity, Weight Loss
Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation
Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and has a grave prognosis. Obesity is an epidemic in the US.Patients with HCC and obesity are not candidates for liver transplantation, depriving…
- Conditions
- Obesity, Weight Loss, Body Weight, Hepatocellular Carcinoma
- Trial name
- NCT02935478
- Testing
- Embospheres Microspheres
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- St. Louis University
Hepatitis B
Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96/384
As part of the CE marking of a hepatitis B diagnostic kit, the South Korean manufacturer Bioneer wishes to set up a performance study in France in accordance with the IVDR (RE 2017/746).
- Trial name
- BIOPERF-HBV (NCT06623071)
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- CerbaXpert
Hepatitis B, Hepatitis C
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
Background: Hepatitis B and hepatitis C can cause liver damage. They can also cause serious illness, including liver cancer, and even death. This study will follow people who have hepatitis B or hepatitis C.
- Conditions
- Hepatitis B, Hepatitis C, HIV-HCV Co-Infection
- Trial name
- NCT01350648
- Where
- 2 sites in United States
- Volunteers
- 569 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Liver Disease
The Physiology of Fatigue in Patients With Chronic Liver Disease
Background: Fatigue is a common and often disabling symptom in people with chronic liver disease. Its causes are not well understood.
- Trial name
- NCT01867385
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Cirrhosis Due to Virus C Chronic Hepatitis
Autologous Bone Marrow Mononuclear Cells in Liver Cirrhosis
This is a phase I clinical study to evaluate feasibility, safety and kinetics of cellular therapy with autologous bone marrow-derived mononuclear cells (BMMC) in patients with liver cirrhosis due to virus C hepatitis.
- Trial name
- CELTHEP-02 (NCT00832247)
- Testing
- Autologous bone marrow mononuclear cells infusion
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Alcoholic Liver Disease, Chronic Hepatitis C Virus Infection
sgp130 in Chronic Human Liver Disease
Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known.
- Trial name
- NCT00770198
- Where
- Belgium
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Chronic Hepatitis C Infection
To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)
This study is designed to evaluate the potential for an effect of Ritonavir (Norvir®) or omeprazole (Prilosec®) on the pharmacokinetics of samatasvir and to assess the safety and tolerability of the study drugs when administered…
- Trial name
- NCT01813552
- Testing
- Samatasvir, Omeprazole, Ritonavir
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis b
ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
Exploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB.
- Trial name
- NCT07573943
- Testing
- Anti-PD-L1 antibody (ASC22), Nucleotide analogs, Peg-IFNα
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Chronic Hepatitis B
3E Extension Study
The purpose of this study is to evaluate the long-term efficacy and safety of entecavir 0.5 mg/d + adefovir 10 mg/d for treatment experienced chronic hepatitis B patients.
- Trial name
- 3E Ex (NCT01834508)
- Testing
- oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
- Where
- 28 sites in China
- Volunteers
- 600 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Chronic Hepatitis B
A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B
An open study to Evaluate the Efficacy, Safety and Sustained effect of Clevudine monotherapy or Adefovir and Clevudine combination in proportion to Roadmap concept in Patients with chronic hepatitis B.
- Trial name
- NCT01264133
- Testing
- Clevudine, Adefovir
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Bukwang Pharmaceutical
Liver Cirrhosis
Intragastric Balloon in Compensated NASH(Non Alcoholic Steato Hepatitis) Cirrhotics
The study will be conducted in department of Hepatology at ILBS, the patients will be recruited from the OPD or IPD . The obese cirrhotic patients with NASH will be observed for standard of care and also patients who undergo IGB…
- Trial name
- NCT03753438
- Testing
- Intragstric Ballooning
- Where
- India
- Volunteers
- 56 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatitis A Virus
Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)
Hepatitis A vaccine will be given either alone or together with measles, mumps, rubella, and varicella vaccine and pneumococcal 7-valent conjugate vaccine at the first dose and together with measles, mumps, rubella, and varicella…
- Trial name
- NCT00312858
- Testing
- Comparator: VAQTA™ (Hepatitis A vaccine), Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine), Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)
- Volunteers
- 653 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
The purpose of this study is to demonstrate the efficacy of TMC435 in combination with peginterferon (PegIFN) + ribavirin (RBV) by means of establishing its non- inferiority compared to an approved regimen of telaprevir + PegIFN…
- Trial name
- ATTAIN (NCT01485991)
- Testing
- TMC435, TVR
- Where
- 137 sites in United States, Argentina and 22 more
- Volunteers
- 771 people
- Sponsor
- Janssen R&D Ireland
Chronic Hepatitis b, Efficacy, Self
Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients
There are chronic hepatitis B patients with poor antiviral efficacy of entecavir in clinical practice. Tenofovir or interferon alfa is the optimal choice right now.
- Trial name
- NCT03733652
- Testing
- Interferon Alfa 2a
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University